63891-88-3

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-broMo-2,2-diMethylacetoacetate is used as an IRAK4 inhibitor for treating a wide range of diseases, including inflammatory, autoimmune, cardiovascular, central nervous system, dermatology, bone, and ophthalmic conditions. Its application as an IRAK4 inhibitor helps in modulating the immune response and reducing inflammation, making it a promising candidate for therapeutic intervention in these diseases.
Additionally, Ethyl 4-broMo-2,2-diMethylacetoacetate has been found to be effective in cancer treatment. As an IRAK4 inhibitor, it can potentially disrupt the signaling pathways involved in cancer cell growth and proliferation, offering a new avenue for cancer therapy.

Upstream product

• 597-04-6 ethyl 2,2-dimethyl-3-oxobutanoate 

Downstream Products

• 155062-15-0 1-benzyl-3,3-dimethylpyrrolidine-2,4-dione 
• 215529-43-4 ethyl 2-[6-[3-[4-(diphenylmethoxy)piperidino]propyl-amino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropionate 
• 215529-48-9 tert-Butyl 2-[6-[3-[4-(diphenylmethoxy)piperidino]-propoxy]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropionate 
• 215529-50-3 2-[6-[3-[4-(diphenylmethoxy)piperidino]-propoxy]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropionic acid 
• 698367-98-5 4-[(E)-4-(5-fluorobenzo[b]thiophen-2-yl)-2-methyl-3-buten-2-yl]-1-triphenylmethyl-1H-imidazole 
• 698367-89-4 2-methyl-2-(1-trityl-1H-imidazol-4-yl)propionic acid ethyl ester 
• 64464-49-9 2-methyl-2-(1-triphenylmethyl-1H-imidazol-4-yl)propanal 
• 66216-06-6 4-(4-chlorophenoxy)-2,2-dimethyl-3-keto-butanoic acid ethyl ester 
• 5436-15-7 3,3-dimethyl-furan-2,4-dione 

Relevant academic research and scientific papers

Synthesis and biological evaluation of simplified mycothiazole analogues

Thiazoline and oxazoline analogues of the natural product mycothiazole were synthesized from a common intermediate and evaluated in vitro against HCT-15 colon cancer cells and L4 larvae of nematode Nippostrongylus brasiliensis. The nature of the heterocyclic moiety seems to modulate the cytotoxic or anthelmintic activity.

8-AMINOISOQUINOLINE CompoundS AND USES THEREOF

3-Carbonylamino-8-aminoisoquinoline Compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The Compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline Compounds.

Synthesis of enantiomerically enriched α,α-disubstituted β,γ-epoxy esters using hydrolytic kinetic resolution catalyzed by salenCo(III)

Novel α,α-disubstituted epoxy esters were prepared in enantiopure form by hydrolytic kinetic resolution (HKR) of the corresponding racemic mixtures using chiral salenCo(III) as catalyst. The methodology provides a convenient route to enantioenriched β,γ-epoxy esters 2a, 2c and 2d.

NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION

The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).

Method for Synthesis of 2,5-Dioxane-1,4-Diones

The invention relates to a novel method for the synthesis of 2,5-dioxane-1,4-diones having formula (I), comprising the oxidation of the ketone function of a cyclic compound having formula (II), wherein R1, R2, R3 and R4 independently represent the hydrogen atom, halo, (C2-C6) alkenyl, (C3-C7)cycloalkyl, cyclohexenyl and a radical having formula —(CH2)m—V—W.